Treatment & Management
The research led by this Think Tank aims to optimize treatment strategies for people living and aging with HIV and STBBIs to promote long-term engagement in care, reduce comorbidities, and improve quality of life.
-
-
CTN 260: Raltegravir switch study
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals
-
CTN 254: Inflammation as a predictor of HIV disease progression
Predictive value of inflammatory biomarkers in untreated HIV disease progression, and their response to initiation of antiretroviral therapy
-
-
CTN 222: Canadian co-infection cohort
A prospective clinical cohort of HIV and hepatitis C virus co-infected patients
-
CTN 242: Canadian observational cohort (CANOC) collaboration
Please Note: This is an observational study and is designed to examine and link HIV/AIDS information drawn from databases across Canada
-
CTN 238: The MAINTAIN study
A randomized control clinical trial of micronutrient and antioxidant supplementation in persons with untreated HIV infection
-
CTN 214: Effect of a one-year course of HAART in acute/early HIV
A randomized trial of highly active antiretroviral therapy in acute/early HIV infection
-
CTN 198: Supportive therapy for adherence with antiretroviral treatment
STAART The purpose of this study was to determine whether a psycho-educational intervention can help people living with HIV handle the challenges of treatment adherence. The study examined the impact of a particular psycho-educational intervention, titled Supportive Therapy for Adherence to Antiretroviral Treatment (STAART), on readiness for treatment, treatment knowledge, coping with side effects, treatment…
-
CTN 227: Hepatitis C therapeutic vaccine
Open label, dose escalating phase I/II study of TG4040 (MVA-HCV) in patients chronically infected with hepatitis C virus (Genotype I) who relapsed from previous pegylated interferon/ribavirin treatment
-
CTN 221: NGX-4010 for the treatment of painful HIV-associated neuropathy
A multicenter randomized, double-blind, controlled study of NGX-4010 for the treatment of painful HIV-associated neuropathy: Trial results